Elisabeth Thijssen, MSc, UCSF Memory and Aging Center, San Francisco, CA, and Amsterdam UMC, Amsterdam, The Netherlands, suggests how phosphorylated tau can be used as a prescreening agent before patients are chosen to partake in clinical trials. Further, phosphorylated tau levels can be measured throughout the trial as it could be a predictive marker and thus reflect target engagement. Thijssen concludes about how, in the future, phosphorylated tau measurements could be a primary marker taken by both GP and memory clinics as a tool for diagnosis. This interview was recorded during an online conference call with The Video Journal of Dementia (VJDementia).
